KR102102267B1 - Pharmaceutical and fool composition comprising lactic acid bacteria complex and N-acetylglucosamin as an active ingredient for preventing or treating skin moisturizing, osteoporosis - Google Patents
Pharmaceutical and fool composition comprising lactic acid bacteria complex and N-acetylglucosamin as an active ingredient for preventing or treating skin moisturizing, osteoporosis Download PDFInfo
- Publication number
- KR102102267B1 KR102102267B1 KR1020190149670A KR20190149670A KR102102267B1 KR 102102267 B1 KR102102267 B1 KR 102102267B1 KR 1020190149670 A KR1020190149670 A KR 1020190149670A KR 20190149670 A KR20190149670 A KR 20190149670A KR 102102267 B1 KR102102267 B1 KR 102102267B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- present
- osteoporosis
- lactic acid
- acid bacteria
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 35
- 241000894006 Bacteria Species 0.000 title claims abstract description 24
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 24
- 239000004310 lactic acid Substances 0.000 title claims abstract description 24
- 239000004480 active ingredient Substances 0.000 title claims description 10
- 230000003020 moisturizing effect Effects 0.000 title description 6
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims abstract description 16
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims abstract description 16
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims abstract description 16
- 229950006780 n-acetylglucosamine Drugs 0.000 claims abstract description 16
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims abstract description 15
- 229940004120 bifidobacterium infantis Drugs 0.000 claims abstract description 15
- 241000194017 Streptococcus Species 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 13
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims abstract description 12
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 12
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 12
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 12
- 241000194031 Enterococcus faecium Species 0.000 claims abstract description 9
- 241000194033 Enterococcus Species 0.000 claims description 10
- 239000002131 composite material Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 7
- 230000000052 comparative effect Effects 0.000 description 56
- 230000000694 effects Effects 0.000 description 23
- 210000000988 bone and bone Anatomy 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 15
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 14
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 14
- 230000037182 bone density Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000000963 osteoblast Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 230000009245 menopause Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 208000029725 Metabolic bone disease Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010049088 Osteopenia Diseases 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000008468 bone growth Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000021067 refined food Nutrition 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- -1 Na-F Chemical compound 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 235000015277 pork Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 244000070406 Malus silvestris Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 235000013324 preserved food Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010016454 Femur fracture Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019990 fruit wine Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019992 sake Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019511 tuna Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Description
본 발명은 유산균 복합균주 및 N-아세틸글루코사민을 유효성분으로 함유하는 피부보습 및 골다공증 예방 또는 치료용 약제학적 조성물, 및 식품 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for preventing or treating skin moisturization and osteoporosis, which contains a lactic acid bacteria complex strain and N-acetylglucosamine as an active ingredient, and a food composition.
우리나라의 노령화 추세가 급속도로 빨라지면서 노령화 사회로 진행하고 있다. 이러한 노령화 사회에서는 다양한 질병이 발생 가능하지만 최근 문제가 되고 있는 골감소증 및 골다공증에 주의를 기울여야 한다. 뼈는 일생 동안 지속적으로 변하는 장기로 년마다 10%의 뼈가 교체되고 1년이 지나면 우리 몸의 뼈는 모두 새로운 뼈로 교체된다. 20대에서 30대까지 골밀도가 가장 높고 그 이후로는 조금씩 감소하다가 여성의 경우 폐경 첫 5년간 급속도로 골밀도가 약해진다 (Ye-Soo Park. Diagnosis and treatment of osteoporosis. J Korean Med Assoc 2012 November; 55(11): 1083-1094).As the trend of aging in Korea is rapidly increasing, it is progressing into an aging society. In this aging society, various diseases may occur, but attention should be paid to osteopenia and osteoporosis, which have recently become a problem. Bones are organs that change continuously throughout life, and 10% of bones are replaced every year, and after a year, all of our bones are replaced with new bones. Bone density is highest from the 20s to 30s and decreases slightly thereafter, and then, in women, the bone density decreases rapidly in the first 5 years of menopause (Ye-Soo Park. Diagnosis and treatment of osteoporosis. J Korean Med Assoc 2012 November; 55 (11): 1083-1094).
골다공증은 골의 양이 감소하고, 골의 강도가 약해져서 작은 충격에도 골절이 일어나기 쉬워지게 되는 질환이다. 골다공증은 그 증세 자체보다는 골의 약화에 따라 초래되는 각종 골절, 특히 대퇴골 골절 또는 척추 골절 등이 장기간 활동을 제한하여 문제가 되며, 노인층 사망의 15% 정도를 차지하는 것으로 알려져 있다. 골다공증의 원인으로는 노령, 운동 부족, 저체중, 흡연, 저칼슘 식이, 폐경, 난소 절제 등으로서, 특히 여성의 경우 30세 이후부터 골 감소가 지속적으로 진행되며, 폐경기에 이르면 호르몬 변화에 의해 골 감소가 급격히 진행된다. 즉, 폐경기에 이르면 에스트로겐 농도가 급속히 감소하는데, 이에 따라 파골 세포의 활성이 증가되어 골에 함유된 칼슘의 양이 감소하게 되고, 골 형태를 유지하는 구조가 약화되게 된다.Osteoporosis is a disease in which the amount of bone decreases and the strength of the bone becomes weak, so that fractures are likely to occur even with a small impact. Osteoporosis is a problem by limiting long-term activities, such as femur fractures or spinal fractures, which are caused by weakening of bones rather than the symptoms themselves, and are known to account for 15% of the deaths of the elderly. The causes of osteoporosis are old age, lack of exercise, low weight, smoking, low calcium diet, menopause, ovarian ablation, etc., especially in women, bone loss continues to progress from the age of 30 and decreases by hormonal changes in menopause. Proceeds rapidly. That is, the estrogen concentration rapidly decreases when menopause is reached, thereby increasing the activity of osteoclasts, thereby reducing the amount of calcium contained in the bone and weakening the structure that maintains bone morphology.
이러한 골다공증을 치료하기 위하여 호르몬, 알렌드로네이트(alendronate), 칼시토닌(calcitonin), 라록시펜(raloxifene), Na-F, 칼시트리올(calcitriol) 또는 비스포스포네이트(bisphosphonate) 제제 등을 투여하게 된다. 그러나, 골다공증의 치료는 장기적인 치료기간을 요구하는 질환이기 때문에 종래의 약물을 장기 복용하게 됨으로써 요로결석, 자궁내막암, 유방암 등과 같은 부작용이 초래될 가능성이 높아진다. 특히, 현재 골다공증 치료제로 널리 사용되는 에스트로겐이나 칼시토닌을 포함한 호르몬 요법의 경우 유방암, 심근경색, 정맥 혈전증 등의 부작용이 보고된 바 있다(JAMA 2002, 288, 872-881; J Obstet Bynaecol Can 2002, 24, 711-715) 또한, 비스포스포네이트는 파골세포를 억제하는 골흡수 억제제로서 새로운 대체 치료제로 주목받고 있으나, 흡수율이 낮다는 문제점이 있고, 올바르지 않은 경구 투여시에는 상기도(upper airway)에 병소가 관찰된다고 보고된 바 있다(Clin Proc 2002, 77, 1031-1043)Hormones, alendronate, calcitonin, raloxifene, Na-F, calcitriol or bisphosphonate preparations are administered to treat osteoporosis. However, because the treatment of osteoporosis is a disease requiring a long treatment period, the possibility of side effects such as urinary tract stones, endometrial cancer, breast cancer, etc. is increased by long-term use of conventional drugs. In particular, in the case of hormone therapy including estrogen or calcitonin, which is currently widely used as an agent for osteoporosis, side effects such as breast cancer, myocardial infarction, and venous thrombosis have been reported (JAMA 2002, 288, 872-881; J Obstet Bynaecol Can 2002, 24 , 711-715) In addition, bisphosphonates are receiving attention as a new alternative treatment as a bone resorption inhibitor that inhibits osteoclasts, but there is a problem of low absorption, and lesions are observed in the upper airway when administered incorrectly. It has been reported (Clin Proc 2002, 77, 1031-1043)
이에 따라, 독성 및 부작용이 적은 치료제의 개발이 절실히 요구되어, 최근에는 다른 부작용 없이 골손실을 최소화하면서 골형성을 촉진할 수 있는 한약재 및 식품 등의 천연물 유래 활성성분을 이용한 대체요법 연구와 다양한 추출물 제조방법이 개발되고 있다. Accordingly, there is an urgent need for the development of therapeutic agents with low toxicity and side effects. Recently, research on alternative therapies using active ingredients derived from natural products such as herbal medicines and foods that can promote bone formation while minimizing bone loss without other side effects and various extracts Manufacturing methods are being developed.
종래기술로서, 등록특허 제1709281호는 생약 추출물 또는 이의 유산균 발효물을 포함하는 골다공증 예방 또는 치료용 조성물에 관한 것으로, 생약 혼합물에 유산균을 접종하여 발효하는 구성을 개시하고 있다. 그런데, 이와 같은 종래의 기술은 생약 혼합물에 유산균을 접종하는 발효하는 과정에서 온도 및 습도 등의 다양한 환경 조건에 따라 효능이 나타나지 않는 문제점이 있다.As a prior art, Patent No. 1,701,9281 relates to a composition for preventing or treating osteoporosis, including a crude drug extract or a lactic acid bacteria fermentation product thereof, and discloses a composition for inoculating lactic acid bacteria in a crude drug mixture to ferment. However, such a conventional technique has a problem in that the efficacy does not appear according to various environmental conditions such as temperature and humidity during fermentation inoculating lactic acid bacteria in the herbal mixture.
이에 본 발명자들은 골다공증에 대한 예방, 개선 효과에 대한 환경 조건의 영향을 최소화하면서 부작용이 적은 천연물을 찾고자 예의 연구 노력한 결과, 유산균 복합균주 및 N-아세틸글루코사민을 포함하는 조성물이 골다공증 및 피부보습에 대한 효능이 있음을 확인하고 본 발명을 완성하였다.Accordingly, the present inventors tried to find a natural product with few side effects while minimizing the effect of environmental conditions on the prevention and improvement effect of osteoporosis, and as a result, a composition comprising a lactic acid bacteria complex strain and N-acetylglucosamine against osteoporosis and skin moisturization After confirming the efficacy, the present invention was completed.
따라서 본 발명의 목적은 유산균 복합균주 및 N-아세틸글루코사민을 유효성분으로 함유하는 피부보습 및 골다공증 예방 또는 치료용 약제학적 조성물, 및 식품 조성물을 제공하는데 있다.Accordingly, an object of the present invention is to provide a pharmaceutical composition for preventing or treating skin moisturization and osteoporosis, and a food composition containing lactic acid bacteria complex strain and N-acetylglucosamine as an active ingredient.
상술한 목적을 달성하기 위한 본 발명의 일 실시예에 따른 피부보습 및 골다공증 예방 또는 치료용 약제학적 조성물은 락토바실러스 델브루엑키(Lactobacillus delbrueckii), 락토바실러스 플란타룸(Lactobacillus plantarum), 스트렙토코커스 살리바리움(Streptococcus salivarium), 비피도박테리움 인판티스(Bifidobacterium infantis) 및 엔테로코커스 패시움(Enterococcus faecium)으로 이루어진 유산균 복합균주; 및 N-아세틸글루코사민 분말;을 유효성분으로 함유한다.The pharmaceutical composition for preventing or treating skin moisturization and osteoporosis according to an embodiment of the present invention for achieving the above object is Lactobacillus delbrueckii, Lactobacillus plantarum, Streptococcus sali Lactobacillus complex strain consisting of Barium (Streptococcus salivarium), Bifidobacterium infantis and Enterococcus faecium; And N-acetylglucosamine powder; as an active ingredient.
본 발명의 용어 ‘유산균 복합균주’란, 세 가지 종 이상의 유산균을 각각 배양하여 얻은 배양물을 일정 비율로 혼합한 배양물 또는 상기 배양물에 프로바이틱스 계열의 미생물이 혼합된 배양물을 의미한다.The term 'lactic acid bacterium complex strain' of the present invention means a culture in which a culture obtained by culturing three or more species of lactic acid bacteria is mixed at a predetermined ratio, or a culture in which probiotic-based microorganisms are mixed in the culture. .
본 발명의 목적상, 상기 유산균 복합균주는 락토바실러스 델브루엑키(Lactobacillus delbrueckii), 락토바실러스 플란타룸(Lactobacillus plantarum), 스트렙토코커스 살리바리움(Streptococcus salivarium), 비피도박테리움 인판티스(Bifidobacterium infantis) 및 엔테로코커스 패시움(Enterococcus faecium)으로 이루어지는 것을 특징으로 한다.For the purposes of the present invention, the lactic acid bacteria complex strain is Lactobacillus delbrueckii, Lactobacillus plantarum, Streptococcus salivarium, Bifidobacterium infantis And Enterococcus faecium.
본 발명에 있어서, 상기 유산균 복합균주는 바람직하게는 락토바실러스 델브루엑키(Lactobacillus delbrueckii), 락토바실러스 플란타룸(Lactobacillus plantarum), 스트렙토코커스 살리바리움(Streptococcus salivarium), 비피도박테리움 인판티스(Bifidobacterium infantis) 및 엔테로코커스 패시움(Enterococcus faecium)을 3:1:2:2:2의 중량비로 혼합한 것을 특징으로 한다.In the present invention, the lactic acid bacteria complex strain is preferably Lactobacillus delbrueckii, Lactobacillus plantarum, Streptococcus salivarium, Bifidobacterium infantis infantis) and Enterococcus faecium in a weight ratio of 3: 1: 2: 2: 2.
본 발명의 용어 "N-아세틸글루코사민" 이란 글루코사민이 아세틸화된 유도체로 이들은 많은 천연 폴리사카라이드의 중요한 구성성분으로, N-아세틸 글루코사민은 조직 재생에 관여하는 단백질 합성에 중요한 성분이기 때문에 위염, 음식물 알러지, 염증성 장질환(inflammatory bowel disease: IBD), 계실염 (diverticulitis) 및 골관절 조직의 대사장애로부터 야기되는 병리학적 질환뿐만 아니라 급성 및 만성형 류마티스 관절염 및 골관절염과 같은 광범위한 질병을 예방 및 치료하는데 있어서 잠재력을 갖고 있다.The term " N-acetylglucosamine " of the present invention is a derivative of glucosamine acetylated, which is an important component of many natural polysaccharides, and because N-acetyl glucosamine is an important component for protein synthesis involved in tissue regeneration, gastritis, food In preventing and treating a wide range of diseases, such as acute and chronic rheumatoid arthritis and osteoarthritis, as well as pathological diseases resulting from allergies, inflammatory bowel disease (IBD), diverticulitis and metabolic disorders of osteoarthritis. It has potential.
본 발명의 N-아세틸글루코사민은 코리네박테리움 등과 같은 미생물 발효를 통하여 제조된 것을 사용할 수 있으며, 공지된 기술에 의하여 제조된 제품을 구입하여 사용할 수도 있다.The N-acetylglucosamine of the present invention may be used through microbial fermentation such as Corynebacterium, or may be used by purchasing a product manufactured by a known technique.
본 발명에서 사용되는 용어, "예방"은 본 발명의 상기 조성물을 개체에 투여하여 골다공증을 억제하거나 지연시키는 모든 행위를 의미한다.As used herein, the term "prevention" refers to any action that inhibits or delays osteoporosis by administering the composition of the present invention to an individual.
본 발명에서 사용되는 용어, "치료"는 본 발명의 상기 조성물을 개체에 투여하여 골다공증 증세가 호전되도록 하거나 이롭게 되도록 하는 모든 행위를 의미한다.As used in the present invention, the term "treatment" refers to any act of administering the composition of the present invention to an individual to improve or benefit osteoporosis symptoms.
본 발명에 있어서, 바람직하게는 상기 조성물의 농도가 400 ㎍/mL 인 것을 특징으로 한다.In the present invention, preferably, the concentration of the composition is characterized in that 400 μg / mL.
본 발명의 일 실시예에 의하면, 조골세포의 알칼린 포스파타제(Alkaline phosphatase: ALP) 활성을 증가시켜 골 성장이 활발히 이루어지고 골 밀도를 증가시킴으로써 골다공증의 예방 또는 개선에 유용하게 사용될 수 있음을 확인하였다(표 2 내지 표 4).According to an embodiment of the present invention, by increasing the activity of alkaline phosphatase (Alkaline phosphatase: ALP) of osteoblasts, it was confirmed that bone growth is actively performed and can be effectively used for prevention or improvement of osteoporosis by increasing bone density. (Tables 2 to 4).
본 발명의 용어, "조골세포"(osteoblast)란, 골아세포로도 불리며, 골기질을 합성하고 분비하여 기질에 Ca, Mg 이온 등의 무기염을 침착시킴으로써 골조직을 석회화시키는 능력을 갖고 있는 세포를 의미한다. 주로 골화 등에 의해 골의 신생이 이루어지는 부위에서 관찰된다.The term "osteoblast" (osteoblast) of the present invention, also called osteoblasts, refers to cells having the ability to calcify bone tissue by synthesizing and secreting bone matrix and depositing inorganic salts such as Ca and Mg ions on the substrate. do. It is mainly observed in areas where bone formation occurs due to ossification.
본 발명의 용어, "골 밀도"(bone density)란, 골의 무기질함량(bone mineral content)의 척도를 의미하며, 골의 단단함을 결정하는 기준이다. 세계보건기구는 젊은 성인들 평균치의 2.5 표준편차 이하의 골밀도, 즉 3% 이하인 경우를 골다공증으로 정의하고 있다. 골밀도는 30세 전후에 최고에 도달한 뒤 5년마다 2%씩 감소되고, 폐경 후에는 이보다 3배쯤 빠른 속도로 감소하게 된다.The term "bone density" of the present invention means a measure of bone mineral content, and is a criterion for determining the rigidity of a bone. The World Health Organization defines osteoporosis as a bone density below 2.5 standard deviations of young adults, ie 3% or less. Bone density decreases by 2% every 5 years after reaching the peak before and after age 30, and after menopause, it decreases by about 3 times faster.
또한, 본 발명의 일 실시예에 의하면, 본 발명의 실시예 1 내지 3은 자외선(UV) 조사군에 비해서 수분함유량(Capacitance(AU))이 유의성 있게 높게 나타난 반면, 비교예 1 내지 12는 자외선 조사군과 대비하여 수분함유량이 비슷하거나 차이가 크지 않음을 확인하였으며, 이러한 결과를 토대로 본 발명의 조성물이 피부 보습효과가 있음을 확인할 수 있었다(표 5).In addition, according to one embodiment of the present invention, Examples 1 to 3 of the present invention showed significantly higher moisture content (Capacitance (AU)) compared to the ultraviolet (UV) irradiation group, whereas Comparative Examples 1 to 12 are ultraviolet Compared to the irradiation group, it was confirmed that the water content was similar or the difference was not large, and based on these results, it was confirmed that the composition of the present invention had a skin moisturizing effect (Table 5).
상기 본 발명의 약제학적 조성물은, 약제학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 또는 희석제를 추가로 포함하는 골다공증 예방 또는 치료용 약학 조성물의 형태로 제조될 수 있다. 이때, 상기 담체는 비자연적인 담체가 될 수 있다. 구체적으로, 상기 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 본 발명에서, 상기 약학적 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물과 이의 분획물들에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는 데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함될 수 있다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The pharmaceutical composition of the present invention may be prepared in the form of a pharmaceutical composition for preventing or treating osteoporosis, further comprising a suitable carrier, excipient or diluent commonly used in the manufacture of pharmaceutical compositions. At this time, the carrier may be an unnatural carrier. Specifically, the pharmaceutical composition is formulated in the form of an oral dosage form such as powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, external preparation, suppository, and sterile injection solution, respectively, according to a conventional method. You can. In the present invention, as a carrier, excipient, and diluent that may be included in the pharmaceutical composition, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate , Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc., which are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations contain at least one excipient, such as starch, calcium carbonate, in the extract and its fractions. It can be prepared by mixing sucrose or lactose, gelatin, and the like. In addition, lubricants such as magnesium stearate and talc may be used in addition to simple excipients. Liquid preparations for oral use may include various excipients, such as wetting agents, sweeteners, flavoring agents, preservatives, etc., in addition to water and liquid paraffin, which are simple diluents commonly used for suspending agents, liquid solutions, emulsions, syrups, etc. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin butter, and glycerogelatin may be used.
상기 본 발명의 약제학적 조성물은 약제학적으로 유효한 양으로 투여될 수 있는데, 본 발명의 용어 "약제학적으로 유효한 양"이란 의학적 치료 또는 예방에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료 또는 예방하기에 충분한 양을 의미하며, 유효 용량 수준은 질환의 중증도, 약물의 활성, 환자의 연령, 체중, 건강, 성별, 환자의 약물에 대한 민감도, 사용된 본 발명 조성물의 투여 시간, 투여 경로 및 배출 비율 치료기간, 사용된 본 발명의 조성물과 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약학 조성물은 단독으로 투여하거나 또는 공지된 골다공증 치료제와 병용하여 투여될 수 있다.The pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount, the term "pharmaceutically effective amount" of the present invention to treat or prevent the disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention Means an amount sufficient, and the effective dose level is the severity of the disease, the activity of the drug, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the time of administration, route of administration and rate of excretion of the composition of the present invention used The duration of treatment, factors including drugs used in combination or coincidental with the composition of the present invention used, and other factors well known in the medical field. The pharmaceutical composition of the present invention may be administered alone or in combination with a known therapeutic agent for osteoporosis.
상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하다.Considering all of the above factors, it is important to administer an amount that can achieve the maximum effect in a minimal amount without side effects.
본 발명의 약제학적 조성물의 투여량은 사용목적, 질환의 중독도, 환자의 연령, 체중, 성별, 기왕력, 또는 유효성분으로서 사용되는 물질의 종류 등을 고려하여 당업자가 결정할 수 있다. 예를 들어, 본 발명의 약학 조성물은 성인 1인당 약 0.1 ng 내지 약 100 mg/kg, 바람직하게는 1 ng 내지 약 10 mg/kg로 투여할 수 있고, 본 발명의 조성물의 투여빈도는 특별히 이에 제한되지 않으나, 1일 1회 투여하거나 또는 용량을 분할하여 수회 투여할 수 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The dosage of the pharmaceutical composition of the present invention can be determined by those skilled in the art in consideration of the purpose of use, the degree of poisoning of the disease, the age, weight, sex, history of the patient, or the type of substance used as an active ingredient. For example, the pharmaceutical composition of the present invention may be administered in an amount of about 0.1 ng to about 100 mg / kg per adult, preferably 1 ng to about 10 mg / kg, and the frequency of administration of the composition of the present invention is particularly limited thereto. Although not limited, it may be administered once a day or may be administered several times by dividing the dose. The above dosage does not limit the scope of the present invention in any way.
본 발명의 골다공증 예방 또는 치료용 약학 조성물의 투여 경로는 어떠한 일반적인 경로를 통하여도 투여될 수 있다. 본 발명의 약제학적 조성물은 특별히 이에 제한되지 않으나, 목적하는 바에 따라 복강내 투여, 정맥내 투여, 근육내 투여, 피하 투여, 피내 투여, 경구 투여, 비내 투여, 폐내 투여, 직장내 투여 등의 경로를 통해 투여 될 수 있다. The route of administration of the pharmaceutical composition for preventing or treating osteoporosis of the present invention can be administered through any general route. The pharmaceutical composition of the present invention is not particularly limited thereto, but the route of intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, intranasal administration, intrapulmonary administration, rectal administration, etc. as desired. Can be administered through.
한편, 본 발명의 다른 일 실시예에 따른 피부보습 및 골다공증 개선 또는 예방용 식품 조성물은 락토바실러스 델브루엑키(Lactobacillus delbrueckii), 락토바실러스 플란타룸(Lactobacillus plantarum), 스트렙토코커스 살리바리움(Streptococcus salivarium), 비피도박테리움 인판티스(Bifidobacterium infantis) 및 엔테로코커스 패시움(Enterococcus faecium)으로 이루어진 유산균 복합균주; 및 N-아세틸글루코사민 분말;을 유효성분으로 함유한다.Meanwhile, the food composition for improving or preventing skin moisturization and osteoporosis according to another embodiment of the present invention is Lactobacillus delbrueckii, Lactobacillus plantarum, Streptococcus salivarium , Lactobacillus complex strain consisting of Bifidobacterium infantis and Enterococcus faecium; And N-acetylglucosamine powder; as an active ingredient.
본 발명에 있어서, 상기 유산균 복합균주는 바람직하게는 락토바실러스 델브루엑키(Lactobacillus delbrueckii), 락토바실러스 플란타룸(Lactobacillus plantarum), 스트렙토코커스 살리바리움(Streptococcus salivarium), 비피도박테리움 인판티스(Bifidobacterium infantis) 및 엔테로코커스 패시움(Enterococcus faecium)을 3:1:2:2:2의 중량비로 혼합한 것을 특징으로 한다.In the present invention, the lactic acid bacteria complex strain is preferably Lactobacillus delbrueckii, Lactobacillus plantarum, Streptococcus salivarium, Bifidobacterium infantis infantis) and Enterococcus faecium in a weight ratio of 3: 1: 2: 2: 2.
본 발명에 있어서, 바람직하게는 상기 조성물의 농도가 400 ㎍/mL 인 것을 특징으로 한다.In the present invention, preferably, the concentration of the composition is characterized in that 400 μg / mL.
본 발명의 용어, "개선"이란, 상기 조성물의 투여로 골다공증이 호전되거나 이롭게 변경되는 모든 행위를 의미한다.The term "improvement" of the present invention means any act of improving or beneficially improving osteoporosis by administration of the composition.
본 발명의 일 실시예로, 상기 식품 조성물을 이용하여 골다공증의 증상을 개선시킬 수 있는 가공식품을 제조할 수 있는데, 예들 들어, 과자, 음료, 주류, 발효식품, 통조림, 우유가공식품, 육류가공식품 또는 국수가공식품의 형태인 건강기능성 식품으로 제조될 수 있다. 이때, 과자는 비스킷, 파이, 케익, 빵, 캔디, 젤리, 껌, 시리얼(곡물푸레이크 등의 식사대용품류 포함) 등을 포함한다. 음료는 음용수, 탄산음료, 기능성 이온음료, 쥬스(예들 들어, 사과, 배, 포도, 알로에, 감귤, 복숭아, 당근, 토마토 쥬스 등), 식혜 등을 포함한다. 주류는 청주, 위스키, 소주, 맥주, 양주, 과실주 등을 포함한다. 발효식품은 간장, 된장, 고추장 등을 포함한다. 통조림은 수산물 통조림(예들 들어, 참치, 고등어, 꽁치, 소라 통조림 등), 축산물 통조림(쇠고기, 돼지고기, 닭고기, 칠면조 통조림 등), 농산물 통조림(옥수수, 복숭아, 파일애플 통조림 등)을 포함한다. 우유가공식품은 치즈, 버터, 요구르트 등을 포함한다. 육류가공식품은 돈까스, 비프까스, 치킨까스, 소세지. 탕수육, 너겟류, 너비아니 등을 포함한다. 밀봉포장생면 등의 국수를 포함한다. 이 외에도 상기 조성물은 레토르트식품, 스프류 등에 사용될 수 있다.In one embodiment of the present invention, a processed food capable of improving the symptoms of osteoporosis may be prepared using the food composition, for example, confectionery, beverage, alcoholic beverage, fermented food, canned food, milk processed food, meat processing It can be manufactured as a health functional food in the form of food or noodles processed food. At this time, the confectionery includes biscuits, pies, cakes, breads, candy, jelly, chewing gum, cereals (including meal substitutes such as cereals and flakes). Beverages include drinking water, carbonated beverages, functional ionic beverages, juices (eg, apples, pears, grapes, aloe, citrus, peaches, carrots, tomato juices, etc.), and sikhye. Alcoholic beverages include sake, whiskey, shochu, beer, liquor, and fruit wine. Fermented foods include soy sauce, miso, and red pepper paste. Canned foods include canned fish (eg, canned tuna, mackerel, saury, turban, etc.), canned livestock products (canned beef, pork, chicken, turkey, etc.), and canned agricultural products (corn, peach, canned file apple, etc.). Milk processed foods include cheese, butter, and yogurt. Processed meat products include pork cutlet, beef cutlet, chicken cutlet and sausage. This includes sweet and sour pork, nuggets, and bread, and so on. Contains noodles such as sealed packaging noodles. In addition to this, the composition may be used for retort food, soups, and the like.
본 발명에 따르면, 본 발명에 따른 유산균 복합균주 및 N-아세틸글루코사민을 유효성분으로 함유하는 피부보습 및 골다공증 예방 또는 치료용 약제학적 조성물, 및 식품 조성물은 조골세포의 알칼린 포스파타제(Alkaline phosphatase: ALP) 활성을 증가시켜 골 성장이 활발히 이루어지고 골 밀도를 증가시킴으로써 골다공증의 예방, 치료 또는 개선에 유용하게 사용될 수 있다.According to the present invention, the pharmaceutical composition for preventing or treating skin moisturizing and osteoporosis containing the lactic acid bacteria complex strain according to the present invention and N-acetylglucosamine as an active ingredient, and the food composition are alkaline phosphatase (ALP) of osteoblasts ) By increasing activity, bone growth is actively performed, and by increasing bone density, it can be usefully used for prevention, treatment, or improvement of osteoporosis.
또한, 본 발명에 따른 조성물은 자외선 조사에 의해 유발된 피부 수분의 손실을 억제하거나 감소시키는 피부 보습의 예방, 치료 또는 개선에 효과가 있다.In addition, the composition according to the present invention is effective in preventing, treating or improving skin moisturizing that suppresses or reduces the loss of skin moisture caused by ultraviolet irradiation.
본 발명은 다양한 변환을 가할 수 있고 여러 가지 실시 예를 가질 수 있는 바, 특정 실시 예들을 상세한 설명에서 상세하게 설명하고자 한다. 그러나, 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변환, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.The present invention can be applied to a variety of transformations and may have various embodiments, and specific embodiments will be described in detail in the detailed description. However, this is not intended to limit the present invention to specific embodiments, and should be understood to include all conversions, equivalents, and substitutes included in the spirit and scope of the present invention. In the description of the present invention, when it is determined that a detailed description of known technologies related to the present invention may obscure the subject matter of the present invention, the detailed description will be omitted.
본 출원에서 사용한 용어는 단지 특정한 실시예를 설명하기 위해 사용된 것으로, 본 발명을 한정하려는 의도가 아니다. 단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한, 복수의 표현을 포함한다. 본 출원에서, "포함하다" 또는 "가지다" 등의 용어는 명세서상에 기재된 특징, 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 다른 특징들이나 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.The terms used in this application are only used to describe specific embodiments, and are not intended to limit the present invention. Singular expressions include plural expressions unless the context clearly indicates otherwise. In this application, the terms "include" or "have" are intended to indicate the presence of features, numbers, steps, actions, components, parts or combinations thereof described herein, one or more other features. It should be understood that the existence or addition possibilities of fields or numbers, steps, operations, components, parts or combinations thereof are not excluded in advance.
이하, 실시예를 통하여 본 발명을 더욱 상세하게 설명하고자 하나, 하기의 실시예는 단지 설명의 목적을 위한 것이며, 본 발명의 범위를 한정하고자 하는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples, but the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
< 실시예 1> <Example 1>
1) 혼합 유산균 제조1) Preparation of mixed lactic acid bacteria
증류수 100 중량부에 우유 10 중량부를 넣고 혼합한 후 살균하였다. 여기에 100 parts by weight of distilled water and 10 parts by weight of milk were mixed and sterilized. Here
락토바실러스 델브루엑키(Lactobacillus delbrueckii), 락토바실러스 플란타룸(Lactobacillus plantarum), 스트렙토코커스 살리바리움(Streptococcus salivarium), 비피도박테리움 인판티스(Bifidobacterium infantis) 및 엔테로코커스 패시움(Enterococcus faecium)을 3:1:2:2:2의 중량비로 혼합하여 상기 혼합 유산균 2 중량부를 접종하고 38 ℃에서 10시간 동안 배양하고, 이를 동결건조하여 유산균 분말을 제조하였다.Lactobacillus delbrueckii, Lactobacillus plantarum, Streptococcus salivarium, Bifidobacterium infantis and Enterococcus facium facium facium Mixing in a weight ratio of 1: 1: 2: 2: 2, inoculated with 2 parts by weight of the mixed lactic acid bacteria, incubated at 38 ° C for 10 hours, and lyophilized to prepare lactic acid bacteria powder.
상기 균주는 국내외 미생물 기탁기관(생명공학연구원 유전자은행, 한국미생물보존센타, 농업유전자자원센터, ATCC(American Type Culture CollectionAsociacin))으로부터 분양받아 사용할 수 있다.The strain can be used by pre-sale from domestic and foreign microbial deposit institutions (Biotechnology Research Institute Gene Bank, Korea Microbial Conservation Center, Agricultural Gene Resource Center, ATCC (American Type Culture CollectionAsociacin)).
2) 조성물 제조2) Composition Preparation
상기 제조한 혼합 유산균 분말에 N-아세틸글루코사민 분말을 혼합하여 본 발명의 조성물을 제조하였다. 이 때 혼합 유산균 분말 100 중량부에 대하여 N-아세틸글루코사민 분말 100 중량부를 사용하였다. The composition of the present invention was prepared by mixing N-acetylglucosamine powder with the prepared lactic acid bacteria powder. At this time, 100 parts by weight of N-acetylglucosamine powder was used relative to 100 parts by weight of the mixed lactic acid bacteria powder.
< 실시예 2~3> <Examples 2 to 3>
상기 실시예 1과 동일한 방법으로 하되, 하기 표 1과 같은 조건으로 실시예 2~3의 조성물을 제조하였다.In the same manner as in Example 1, the compositions of Examples 2 to 3 were prepared under the same conditions as Table 1 below.
<비교예 1~12><Comparative Examples 1-12>
상기 실시예 1과 동일한 방법으로 하되, 하기 표 1과 같은 조건으로 비교예 1~12의 조성물을 제조하였다.In the same manner as in Example 1, the compositions of Comparative Examples 1 to 12 were prepared under the same conditions as Table 1 below.
< 실험예 1> 본 발명의 조성물의 세포독성 평가 <Experimental Example 1> Cytotoxicity evaluation of the composition of the present invention
상기 실시예 1~3에 따라 제조한 본 발명의 조성물의 안전성을 확인하기 위하여, 조골세포에 대한 상기 조성물의 세포독성을 평가하였다. 구체적으로, 96 웰 플레이트에 조골세포주 C3H10T1/2를 2×102 세포/웰로 계수하여 분주하였고, 본 발명의 조성물을 세포에 처리 하기 전 1시간 정도 멸균 증류수에 넣어 200, 400 및 600 ㎍/mL 농도의 조성물을 제조하고, 상기 제조된 200, 400 및 600 ㎍/mL 농도의 조성물을 상기 세포에 처리하여 24시간 또는 72시간 동안 배양하였다. 배양 완료 후, MTT 용액의 추가에 의하여 형성된 비수용성의 포르마잔(formazan)을 디메틸술폭시드(dimethyl sulfoxide) 용액으로 용해시켰으며, 595nm에서 상기 용해된 포르마잔의 흡광도를(optical density; OD value) 측정함으로써 상대적인 세포 활성능(%)을 평가하였다.In order to confirm the safety of the composition of the present invention prepared according to Examples 1 to 3, the cytotoxicity of the composition against osteoblasts was evaluated. Specifically, the osteoblast cell line C3H10T1 / 2 was counted and divided into 2 × 10 2 cells / well in a 96-well plate, and 200, 400 and 600 μg / mL were put into sterile distilled water for about 1 hour before processing the composition of the present invention into cells. Concentration compositions were prepared, and the prepared 200, 400, and 600 μg / mL concentration compositions were treated with the cells and cultured for 24 hours or 72 hours. After completion of the culture, the water-insoluble formazan formed by the addition of the MTT solution was dissolved with a dimethyl sulfoxide solution, and the absorbance of the dissolved formazan at 595 nm (optical density; OD value). The relative cell activity (%) was evaluated by measurement.
그 결과, 표 2의 세포 활성능(%) 결과에서 볼 수 있듯이, 본 발명의 실시예 1~3의 조성물은 200, 400 및 600 ㎍/mL의 농도에서도 대조구와 대비하여 세포독성을 나타내지 않음을 확인하였다.As a result, as can be seen from the cell activity (%) results in Table 2, the compositions of Examples 1 to 3 of the present invention did not show cytotoxicity compared to the control even at concentrations of 200, 400 and 600 µg / mL. Confirmed.
조성물 처리200 μg / mL
Composition treatment
조성물 처리400 μg / mL
Composition treatment
조성물 처리600 μg / mL concentration
Composition treatment
<실험예 2> 알칼린 포스파타제(Alkaline phosphatase: ALP) 활성의 측정 <Experimental Example 2> Measurement of alkaline phosphatase (Alkaline phosphatase: ALP) activity
골 성장이 활발히 이루어질 때에는 ALP의 합성이 증가하게 된다. 이를 확인하기 위하여, 세포가 90% 포화도에 도달하였을 때, 10 mM β-글리세로포스페이트 및 50 ㎍/㎖ 아스코르브산을 함유하는 배양 배지로 세포를 처리하여 시험관내 미네랄화를 개시하였다. 상기 배지는 2-3일마다 교체하였다. 6일 후, 세포를 0.3% 소 혈청 알부민(BSA) 및 단리된 화합물을 함유하는 배지를 이용하여 2일 동안 개별적으로 배양하였다. 수확시, 상기 배지를 제거하였고, 세포 단일층을 PBS(Phosphate-buffered saline)를 이용하여 2회 부드럽게 세척하였다. 상기 세포를 0.2% 트리톤 X-100을 이용하여 용해시켰다. 상기 용해물을 14,000×g에서 5분 동안 원심분리하였다. 투명한 상등액을 사용하여 ALP 활성 분석 키트(Asan Co., Ansan, Korea)를 이용하여 ALP 활성을 측정하였다.When bone growth is active, the synthesis of ALP increases. To confirm this, when the cells reached 90% saturation, in vitro mineralization was initiated by treating the cells with a culture medium containing 10 mM β-glycerophosphate and 50 μg / ml ascorbic acid. The medium was changed every 2-3 days. After 6 days, cells were cultured individually for 2 days using a medium containing 0.3% bovine serum albumin (BSA) and isolated compound. Upon harvesting, the medium was removed and the cell monolayer was gently washed twice with PBS (Phosphate-buffered saline). The cells were lysed using 0.2% Triton X-100. The lysate was centrifuged at 14,000 × g for 5 minutes. ALP activity was measured using an ALP activity assay kit (Asan Co., Ansan, Korea) using a clear supernatant.
그 결과, 표 3에서 나타난 바와 같이, 본 발명의 조성물은 200, 400 및 600 ㎍/mL의 농도에서도 조골세포주 C3H10T1/2에서의 ALP 활성(대조구 대비 %)을 증가시켰다. 특히, 본 발명의 조성물은 400 ㎍/mL의 농도에서 가장 높은 ALP 활성을 나타내었다.As a result, as shown in Table 3, the composition of the present invention increased the ALP activity (% relative to the control) in the osteoblast cell line C3H10T1 / 2 even at concentrations of 200, 400 and 600 μg / mL. In particular, the composition of the present invention showed the highest ALP activity at a concentration of 400 μg / mL.
조성물 처리200 μg / mL
Composition treatment
조성물 처리400 μg / mL
Composition treatment
조성물 처리600 μg / mL concentration
Composition treatment
<실험예 3> 골 밀도에 대한 본 발명의 조성물의 영향 <Experimental Example 3> Effect of the composition of the present invention on bone density
본 발명의 조성물이 외과적으로 난소를 제거하여 골감소증을 유발한 동물모델의 골 밀도에 미치는 영향을 분석하였다.The effects of the composition of the present invention on the bone density of an animal model induced osteopenia by surgically removing ovaries were analyzed.
8주령의 암컷 C57BL/6 mice를 이용하여 난소를 제거하여 폐경기 골감소증 질환동물을 제작하였으며, 난소 제거를 위해 복부 아래쪽 가운데 구역에 1-2cm정도 피부 절개 후 포셉(forcep)을 이용하여 난소(ovary)와 난관(oviduct) 등을 견인하여 절제하였다. 난소 제거 1주일 후, 체중 측정을 통하여 무작위적으로 그룹(randomized grouping)을 나누었으며, 존데(Sonde)를 이용하여 본 발명의 조성물 1mg/kg 용량으로 주 6회 경구 투여하였다.The ovaries were removed using 8-week-old female C57BL / 6 mice to produce menopausal osteopenia disease animals. To remove the ovaries, a 1-2 cm skin cut was made in the lower middle area of the abdomen and forceps were used to ovary. And the oviduct were towed and excised. One week after removal of the ovaries, randomized grouping was divided through weight measurement and orally administered 6 times a week at a dose of 1 mg / kg of the composition of the present invention using Sonde.
투여 종료 후, 대퇴골을 분리하여 주변 근육을 제거하였고, 10% 포르말린으로 고정하였다. μCT 분석을 통해 골밀도를 측정하였으며, 대퇴골 원위부 골단에서 골의 전체 면적에 대한 해면골의 부피를 산출하여 골감소증에 대한 치료효과를 평가하였다.After the end of administration, the femur was removed to remove the surrounding muscles and fixed with 10% formalin. Bone density was measured through μCT analysis, and the volume of spongy bone over the entire area of the distal femur was calculated to evaluate the therapeutic effect on osteopenia.
그 결과, 표 4에서 보듯이, 폐경으로 인하여 골감소증이 유발된 음성 대조군에 비하여, 400㎍/mL의 본 발명의 조성물을 투여한 실험군인 실시예 1 내지 실시예 3은 대퇴골 원위부 골단의 해면골의 골 부피 밀도(Bone volume density, BV/TV (%))가 증가되는 것을 확인하였다.As a result, as shown in Table 4, compared to the negative control group induced osteopenia due to menopause, Example 1 to Example 3, which is an experimental group in which the composition of the present invention was administered at 400 µg / mL, was a bone of the spongy bone of the distal femur. It was confirmed that the volume density (Bone volume density, BV / TV (%)) was increased.
반면, 비교예 1 내지 12를 동일 용량으로 경구 투여한 경우는 음성 대조군과 대비하여 골 부피 밀도의 변화가 거의 없음을 확인할 수 있다.On the other hand, when Comparative Examples 1 to 12 were administered orally in the same dose, it can be confirmed that there was almost no change in bone volume density compared to the negative control.
(Bone volume density, BV/TV (%))Bone volume density
(Bone volume density, BV / TV (%))
유발군menopause
Trigger group
상기 결과를 통해, 본 발명의 조성물은 ALP의 합성이 유의적으로 증가하여 골 성장이 활발히 이루어지고 골 밀도를 증가시킴으로써 골다공증을 치료하는 효과를 나타냄을 알 수 있었다.Through the above results, it was found that the composition of the present invention exhibits an effect of treating osteoporosis by significantly increasing the synthesis of ALP, thereby actively improving bone growth, and increasing bone density.
<실험예 4> 피부 보습에 대한 본 발명의 조성물의 영향 <Experimental Example 4> Effect of the composition of the present invention on skin moisturizing
1) 실험동물 및 시료투여1) Experiment animal and sample administration
실험동물로는 7주령의 수컷 무모 생쥐(male HR-1, hairless mice, Japan SLC, Inc)를 중앙실험동물로부터 구입하여 1주 동안 적응시킨 후 사용하였다. 적응기간 중 일반 상태를 관찰하여 건강한 상태의 동물을 시험에 사용하였다. 사육환경은 온도 23±3℃, 습도 50±5%, 명암주기 12시간 (07:00-19:00/조명시간)으로 유지하였다. 시험기간 중 실험동물은 폴리카보네이트(polycarbonate) 케이지(200×320×145mm, Three-shine Co, Daejeon,Korea)에 군당 5마리로 사육하였고 사료는 마우스 전용사료 5L79 (Charles river, USA)를 자유급이하였으며, 음수는 자외선으로 소독한 상수도수를 자유급이하였다.As experimental animals, 7-week-old male hairless mice (male HR-1, hairless mice, Japan SLC, Inc) were purchased from a central laboratory animal and used after being adapted for 1 week. During the acclimatization period, the general condition was observed and the healthy animal was used for the test. The breeding environment was maintained at a temperature of 23 ± 3 ℃, a humidity of 50 ± 5%, and a contrast cycle of 12 hours (07: 00-19: 00 / lighting time). During the test period, the experimental animals were bred in a polycarbonate cage (200 × 320 × 145mm, Three-shine Co, Daejeon, Korea) at a rate of 5 animals per group, and the feed was freely supplied with mouse feed 5L79 (Charles river, USA). The drinking water was freely supplied with drinking water sterilized by ultraviolet light.
실시예 1 내지 3, 및 비교예 1 내지 12 각각에 대한 시료투여는 마우스 존대를 이용하여 경구 투여를 실시하였다. 투여기간은 총 8주로 주 5일 동안 투여하였다.Sample administration for each of Examples 1 to 3 and Comparative Examples 1 to 12 was performed orally using a mouse zone. The administration period was 8 weeks in total and was administered for 5 days a week.
2) 자외선 조사2) UV irradiation
자외선 조사는 대조군을 제외한 실시예 1 내지 3, 및 비교예 1 내지 12에 8주 동안 주 3회 실시하였고, 자외선은 UV 램프(Mineralight UV Display lamp, UVP, USA)를 사용하였다. 자외선 조사량은 1 내지 7주간은 60 mJ/cm2, 8-12주는 90 mJ/cm2로 12 주 동안 조사하였다. 자외선 조사량은 광측정기(Delta OHM, Italy)를 이용하여 광량을 측정한 후, 조사시간으로 조절하였다.Ultraviolet irradiation was carried out three times a week for 8 weeks in Examples 1 to 3, and Comparative Examples 1 to 12, excluding the control group, and the UV was used as a UV lamp (Mineralight UV Display lamp, UVP, USA). The irradiation dose was 60 mJ / cm 2 for 1 to 7 weeks and 90 mJ / cm 2 for 8-12 weeks for 12 weeks. The ultraviolet dose was measured by using a photometer (Delta OHM, Italy), and then adjusted to the irradiation time.
3) 피부수분량 측정3) Measurement of skin moisture
피부수분량은 항온 및 항습 조건(23℃, 상대습도 50%)에서 코니오미터(Corneometer Courage & Khazaka,Germany) 장비를 이용하여 피부에 함유된 수분을 측정하였다. 피부의 표피 내에 존재하는 수분의 양은 센서를 이용하여 수분의 이온 정도를 측정하고, 이를 수치화하여 수분의 양을 계산함으로써 보습력을 측정하였다. 본 실시예에서 획득한 결과는 통계분석 프로그램(one-way ANOVA와 Student t-test)을 이용하여 대조군과 실시예 및 비교예 간의 유의성을 검정하였다. 표 5에서와 같이 실시예 1 내지 3은 자외선(UV) 조사군에 비해서 수분함유량(Capacitance(AU))이 유의성 있게 높게 나타났다. 반면, 비교예 1 내지 12는 자외선 조사군과 대비하여 수분함유량이 비슷하거나 차이가 크지 않다. 이러한 결과를 토대로 실시예 1 내지 3이 피부 보습효과가 있음을 확인할 수 있었다.The moisture in the skin was measured by using a Cornneometer Courage & Khazaka (Germany) equipment under constant temperature and humidity conditions (23 ° C, 50% relative humidity). The amount of moisture present in the epidermis of the skin was measured using a sensor to measure the degree of ions of moisture, and by quantifying it, moisture was measured by calculating the amount of moisture. The results obtained in this example were tested for significance between the control group and the examples and comparative examples using a statistical analysis program (one-way ANOVA and Student t-test). As shown in Table 5, Examples 1 to 3 showed significantly higher moisture content (Capacitance (AU)) than the ultraviolet (UV) irradiation group. On the other hand, in Comparative Examples 1 to 12, the moisture content is similar or the difference is not large compared to the ultraviolet irradiation group. Based on these results, it was confirmed that Examples 1 to 3 had a skin moisturizing effect.
한편, 이상의 상세한 설명은 모든 면에서 제한적으로 해석되어서는 아니되고 예시적인 것으로 고려되어야 한다. 본 발명의 범위는 첨부된 청구항의 합리적 해석에 의해 결정되어야 하고, 본 발명의 등가적 범위 내에서의 모든 변경은 본 발명의 범위에 포함된다.Meanwhile, the above detailed description should not be construed as limiting in all respects and should be considered as illustrative. The scope of the present invention should be determined by rational interpretation of the appended claims, and all changes within the equivalent scope of the present invention are included in the scope of the present invention.
Claims (3)
N-아세틸글루코사민 분말;을 유효성분으로 함유하는 골다공증 예방 또는 치료용 약제학적 조성물로서,
상기 락토바실러스 델브루엑키(Lactobacillus delbrueckii), 락토바실러스 플란타룸(Lactobacillus plantarum), 스트렙토코커스 살리바리움(Streptococcus salivarium), 비피도박테리움 인판티스(Bifidobacterium infantis) 및 엔테로코커스 패시움(Enterococcus faecium)의 중량비가 3:1:2:2:2 이고,
상기 조성물의 농도가 400 ㎍/mL 인 것을 특징으로 하는 골다공증 예방 또는 치료용 약제학적 조성물.
Enterococcus facium consisting of Lactobacillus delbrueckii, Lactobacillus plantarum, Streptococcus salivarium, Bifidobacterium infantis and Enterococcus facium consisting of Bifidobacterium infantis and Enterococcus faecium Lactic acid bacteria complex strain; And
N- acetylglucosamine powder; as a pharmaceutical composition for preventing or treating osteoporosis containing as an active ingredient,
The Lactobacillus delbrueckii, Lactobacillus plantarum, Streptococcus salivarium, Bifidobacterium infantis and Enterococcus facus of Enterococcus facium The weight ratio is 3: 1: 2: 2: 2,
Pharmaceutical composition for preventing or treating osteoporosis, characterized in that the concentration of the composition is 400 ㎍ / mL.
N-아세틸글루코사민 분말;을 유효성분으로 함유하는 골다공증 개선 또는 예방용 식품 조성물로서,
상기 락토바실러스 델브루엑키(Lactobacillus delbrueckii), 락토바실러스 플란타룸(Lactobacillus plantarum), 스트렙토코커스 살리바리움(Streptococcus salivarium), 비피도박테리움 인판티스(Bifidobacterium infantis) 및 엔테로코커스 패시움(Enterococcus faecium)의 중량비가 3:1:2:2:2 이고,
상기 조성물의 농도가 400 ㎍/mL 인 것을 특징으로 하는 골다공증 개선 또는 예방용 식품 조성물.
Enterococcus facium consisting of Lactobacillus delbrueckii, Lactobacillus plantarum, Streptococcus salivarium, Bifidobacterium infantis and Enterococcus facium consisting of Bifidobacterium infantis and Enterococcus faecium Lactic acid bacteria complex strain; And
N- acetylglucosamine powder; as an active ingredient for improving or preventing osteoporosis food composition,
The Lactobacillus delbrueckii, Lactobacillus plantarum, Streptococcus salivarium, Bifidobacterium infantis and Enterococcus facus of Enterococcus facium The weight ratio is 3: 1: 2: 2: 2,
Food composition for improving or preventing osteoporosis, characterized in that the concentration of the composition is 400 ㎍ / mL.
상기 유산균 복합균주는 38 ℃에서 10시간 동안 배양하고 동결건조하여 제조된 유산균 분말인 것을 특징으로 하는 골다공증 개선 또는 예방용 식품 조성물.
According to claim 2,
The lactic acid bacteria composite strain is a food composition for improving or preventing osteoporosis, characterized in that the lactic acid bacteria powder prepared by incubating at 38 ℃ for 10 hours and lyophilized.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190149670A KR102102267B1 (en) | 2019-11-20 | 2019-11-20 | Pharmaceutical and fool composition comprising lactic acid bacteria complex and N-acetylglucosamin as an active ingredient for preventing or treating skin moisturizing, osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190149670A KR102102267B1 (en) | 2019-11-20 | 2019-11-20 | Pharmaceutical and fool composition comprising lactic acid bacteria complex and N-acetylglucosamin as an active ingredient for preventing or treating skin moisturizing, osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102102267B1 true KR102102267B1 (en) | 2020-04-22 |
Family
ID=70472969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190149670A KR102102267B1 (en) | 2019-11-20 | 2019-11-20 | Pharmaceutical and fool composition comprising lactic acid bacteria complex and N-acetylglucosamin as an active ingredient for preventing or treating skin moisturizing, osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102102267B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023075571A1 (en) * | 2021-11-01 | 2023-05-04 | (주)네오리젠바이오텍 | Use of polysaccharides derived from strains of enterococcus genus |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012162473A (en) * | 2011-02-04 | 2012-08-30 | Takeshi Matsuzaki | Composition containing n-acetylglucosamine |
| KR20130002543A (en) * | 2011-06-29 | 2013-01-08 | 주식회사 쎌바이오텍 | Composition for preventing or treating osteoporosis comprising multi-species pobiotic mixture |
| JP2017008095A (en) * | 2012-02-14 | 2017-01-12 | ザ プロクター アンド ギャンブル カンパニー | Topical use of skin-commensal prebiotic agent and compositions containing the same |
| KR101709281B1 (en) | 2010-06-29 | 2017-02-24 | 한국 한의학 연구원 | Composition for Prevention or Treatment of Osteoporosis Comprising Herbal Extract and Fermentation Product thereof with Lactic acid Bacteria |
| JP2017081865A (en) * | 2015-10-30 | 2017-05-18 | 森永乳業株式会社 | Bone disease improver |
| KR20180049729A (en) * | 2016-11-03 | 2018-05-11 | 주식회사 쎌바이오텍 | Composition for antioxidation and improvement of skin conditions |
-
2019
- 2019-11-20 KR KR1020190149670A patent/KR102102267B1/en active IP Right Grant
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101709281B1 (en) | 2010-06-29 | 2017-02-24 | 한국 한의학 연구원 | Composition for Prevention or Treatment of Osteoporosis Comprising Herbal Extract and Fermentation Product thereof with Lactic acid Bacteria |
| JP2012162473A (en) * | 2011-02-04 | 2012-08-30 | Takeshi Matsuzaki | Composition containing n-acetylglucosamine |
| KR20130002543A (en) * | 2011-06-29 | 2013-01-08 | 주식회사 쎌바이오텍 | Composition for preventing or treating osteoporosis comprising multi-species pobiotic mixture |
| JP2017008095A (en) * | 2012-02-14 | 2017-01-12 | ザ プロクター アンド ギャンブル カンパニー | Topical use of skin-commensal prebiotic agent and compositions containing the same |
| JP2017081865A (en) * | 2015-10-30 | 2017-05-18 | 森永乳業株式会社 | Bone disease improver |
| KR20180049729A (en) * | 2016-11-03 | 2018-05-11 | 주식회사 쎌바이오텍 | Composition for antioxidation and improvement of skin conditions |
Non-Patent Citations (1)
| Title |
|---|
| Molecules 2018, 23, 2302; doi:10.3390/molecules23092302* * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023075571A1 (en) * | 2021-11-01 | 2023-05-04 | (주)네오리젠바이오텍 | Use of polysaccharides derived from strains of enterococcus genus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101494279B1 (en) | Lactobacillus plantarum KY1032 having inhibitory activity against adipocyte-specific gene expression and adipocyte differentiation, and product containing thereof as an effective factor | |
| EP2481298A2 (en) | Use of plant extracts as prebiotics, compostions and foods containing such extracts | |
| AU2017337936B2 (en) | Novel Lactobacillus Sakei And Composition Comprising The Same | |
| KR20200104126A (en) | Composition for improving, preventing or treating bone diseases comprising Lactobacillus sakei CVL-001 or culture medium thereof | |
| KR20170123122A (en) | Pharmaceutical composition, food composition or food additives for prevention, improvement or treatment of muscle loss, weakening, and atrophy comprising Enterococcus faecalis, it culture broth or heat killed Enterococcus faecalis as an active ingredient | |
| KR20180008018A (en) | Composition for preventing or treating of colitis disease comprising Lactobacillus sakei K040706 as an active ingredient | |
| KR20200054796A (en) | Lactic acid bacteria for improving liver function and uses thereof | |
| KR102102267B1 (en) | Pharmaceutical and fool composition comprising lactic acid bacteria complex and N-acetylglucosamin as an active ingredient for preventing or treating skin moisturizing, osteoporosis | |
| JP2021503483A (en) | Composition for prevention, amelioration or treatment of bone loss disease containing CHP (cyclo-hispro) | |
| US20080113038A1 (en) | Composition For Promoting Osteogenesis And Increasing Bone Mineral Content | |
| KR102144838B1 (en) | Composition for improving, preventing or treating bone diseases comprising Lactobacillus curvatus WiKim38 or culture medium thereof | |
| KR20180075763A (en) | Composition comprising the ethanol extract of Portulacea oleracea for preventing and treating of Alcoholic liver damage | |
| KR20180134161A (en) | Composition for preventing, improving or depression or anxiety comprising tart cherry extract and fermented rice germ extract | |
| US8367060B2 (en) | Pharmaceutical composition containing arazyme for the prevention of liver dysfunction | |
| US11679134B2 (en) | Pharmaceutical composition, food composition and food additive for preventing, alleviating or treating muscle loss, weakness and atrophy, containing, as active ingredient, Enterococcus faecalis, culture liquid thereof or dead cells thereof | |
| KR20200120549A (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
| WO2007034958A1 (en) | Anti-angiogenic composition comprising grain-derived component as active ingredient | |
| KR101629642B1 (en) | Food composition, pharmaceutical composition, animal medicine and feed composition against fatty liver with piperlongumine | |
| KR101970353B1 (en) | Composition for preventing or treating bone disease comprising mollugin and BMP-2 | |
| US10961176B2 (en) | Compound hexadecaphlorethol isolated from Ishige okamurae and use thereof | |
| KR101532307B1 (en) | Pharmaceutical compositions having anti-metastasis activity comprising extract of bambusae caulis in taeniam | |
| KR20170106627A (en) | Pharmaceutical composition for treating and inhibiting metastasis of glioblastoma comprising protopanaxadiols compound | |
| JP2021500382A (en) | Composition for prevention or improvement of non-alcoholic fatty liver disease | |
| KR101830480B1 (en) | Pharmaceutical composition for preventing or treating hypertriglyceridemia comprising methyl linolenate | |
| KR20160149664A (en) | Composition for preventing, improving or treating of arthritis comprising boswellia serrata extract, grape seed extract and juniperus communis extract as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| N231 | Notification of change of applicant | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |